Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
OCS
OCS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OCS News
Oculis Receives EMA PRIME Designation for Privosegtor
8h ago
Newsfilter
Oculis Secures PRIME Designation for Privosegtor, Advancing Development
7h ago
Yahoo Finance
Oculis Announces Upcoming Investor Conference Schedule
Mar 05 2026
Newsfilter
Oculis Reports 2025 Financial Results and Clinical Milestones
Mar 04 2026
NASDAQ.COM
Oculis Holding Reports Q4 Earnings Beat Expectations
Mar 03 2026
seekingalpha
Oculis Appoints New Chief Legal Officer to Enhance Leadership
Feb 17 2026
Newsfilter
Oculis Receives FDA Breakthrough Therapy Designation, Potential Market Exceeds $7 Billion
Jan 08 2026
Globenewswire
Oculis Receives FDA Breakthrough Therapy Designation, Potential Market Exceeds $7 Billion
Jan 08 2026
Globenewswire
Oculis Receives Breakthrough Therapy Designation, Potential Market Exceeds $7 Billion
Jan 08 2026
Yahoo Finance
US Stock Indices Hit Record Highs as Chip Stocks Rally
Jan 07 2026
NASDAQ.COM
US Stocks Rise with Chipmakers Leading Gains as Copper Prices Hit All-Time High
Jan 06 2026
NASDAQ.COM
Copper Prices Hit All-Time High, Mining Stocks Surge
Jan 06 2026
NASDAQ.COM
U.S. Stocks Rise as Microchip Technology Raises Q3 Revenue Outlook to $1.185 Billion
Jan 06 2026
Benzinga
Oculis (OCS) Receives FDA Breakthrough Therapy Designation for Privosegtor, Showing Significant Vision Improvement
Jan 06 2026
NASDAQ.COM
Oculis' Privosegtor Receives FDA Breakthrough Therapy Designation, Targeting $7 Billion Market
Jan 06 2026
Globenewswire
Oculis' Privosegtor Receives FDA Breakthrough Therapy Designation, Targeting $7 Billion Market
Jan 06 2026
Globenewswire
Show More News
